Lung Progenitor Cell Generation for Alveolar Replacement Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary diseases such as idiopathic pulmonary fibrosis (IPF) and childhood interstitial lung disease (chILD) are inadequate, with lung transplantation being the only life-saving option but having a low survival rate, and there is a lack of effective cell replacement therapy targeting alveolar epithelial cells.
Innovation Solution
A method is developed to generate lung progenitor cells from mammalian pluripotent stem cells using specific growth factors and culture conditions, including GSK inhibitors, BMP agonists, FGF agonists, and retinoic acid, to produce lung bud organoids that can be cultured to generate lung progenitor cells expressing markers like FOXA2, NKX2.1, and PDGFRa, which can be used for cell replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lung transplantation is performed to treat IPF and severe chILD, then life-saving treatment is achieved, but 5-year survival rate is only 59% and morbidity is incapacitating
Solution Approach 1:
The patent extracts and replaces only the damaged alveolar epithelial cells through cell replacement therapy, rather than performing complete lung transplantation. This targeted approach uses genetically corrected AT2 cells or distal lung stem cells to replenish damaged cell populations, avoiding the complexities and risks of full organ transplantation while achieving therapeutic benefit
Solution Approach 2:
The patent creates genetically corrected copies of healthy alveolar epithelial cells (AT2 cells or distal lung stem cells) that can replace damaged cells in the patient's lung. These corrected cells are derived from the patient's own cells through gene editing, then transplanted back to replace dysfunctional cells, providing a personalized cell replacement therapy that avoids transplantation complexity
2Reliability
If cell replacement therapy targets only AT2 cells, then surfactant production is restored, but durable improvement is not achieved because distal lung stem cell compartment is not replaced
Solution Approach 1:
The patent performs preliminary genetic correction of distal lung stem cells before transplantation, ensuring that the corrected cells can provide long-term durable improvement. By correcting the genetic defect in the stem cell compartment first, the therapy establishes a self-renewing population of healthy cells that will continuously produce functional alveolar epithelial cells, ensuring lasting therapeutic effect rather than temporary relief
Solution Approach 2:
The patent uses distal lung stem cells that can differentiate into multiple cell types including AT2 cells, AT1 cells, and other alveolar epithelial cells. This multi-functional cell population can replace various damaged cell types in the lung, providing broader therapeutic coverage than AT2-specific approaches while ensuring durable improvement through stem cell self-renewal
3Manufacturing precision
If genetic therapy vectors are designed to target alveolar epithelial cells, then gene correction is achieved, but vectors that specifically and efficiently target these cells have not been identified
Solution Approach 1:
The patent uses lentiviral vectors that can transduce both dividing and non-dividing cells, allowing the vector to deliver genetic material directly to alveolar epithelial cells and distal lung stem cells without requiring complex cell division synchronization or specialized delivery conditions. The vectors self-propagate and efficiently infect target cells through their natural biological mechanisms, achieving precise gene targeting without complicating the manufacturing process
Solution Approach 2:
The patent modifies vector parameters by using lentiviral vectors with specific properties that enable efficient transduction of alveolar epithelial cells. By changing the vector type from traditional AAV or adenoviral vectors to lentiviral vectors, the system achieves both specific targeting and efficient delivery, as lentiviral vectors can infect both dividing and non-dividing cells and have high transduction efficiency in respiratory epithelial cells
Data Source
AI summary
Disclosed are lung progenitor cells and methods of generating the lung progenitor cells starting from mammalian pluripotent stem cells. The lung progenitors can be used as therapeutic treatments for various pulmonary disorders or injuries. The lung progenitor cells may also be used to model lung diseases/conditions and screen for desired agents.